Perry Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Perry Shen has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Harveshp Mogal
Department of Surgery, University of Washington Medical Center, Seattle, USA
17 shared publications - Timothy Michael Pawlik
Department of Surgery The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center Columbus Ohio USA
16 shared publications Edward A. Levine
Division of Surgical Oncology, Department of General Surgery, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, USA
15 shared publications- George A. Poultsides
Department of Surgery, Stanford University, Stanford, CA, USA
15 shared publications - Cristian D. Valenzuela
Division of Surgical Oncology, Comprehensive Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, USA
13 shared publications Konstantinos I. Votanopoulos
Section of Surgical Oncology, Atrium Health Wake Forest Baptist, Winston-Salem, USA
12 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (7) , 1974-1981
Readmissions After Surgery for Colorectal Liver Metastases: A Propensity Score Analysis From the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC)
Background: Readmission is considered as a surgical quality indicator. More data regarding predictors of readmission and outcomes after surgery for colorectal liver metastasis are needed. Using a propensity score match to create a 1:2 match of cases:controls for 90‐day. Readmission, the matching variables used for balance included age, tumor size, estimated blood loss, and type of resection (minor or major). T‐tests were used for continuous measures, Fisher's exact test was used for categorical data, and the Kaplan–Meier method was used to estimate survival. p < 0.05 was considered significant. Methods: Retrospectively examined 935 patients with CLM from 2000 to 2018. Using a propensity score match to create a 1:2 match of cases:controls for 90‐day. Readmission, the matching variables used for balance included age, tumor size, estimated blood loss, and type of resection (minor or major). T‐tests were used for continuous measures, Fisher's exact test was used for categorical data, and the Kaplan–Meier method was used to estimate survival. p < 0.05 was considered significant. Results: 935 patients were included in the initial sample with 896 eligible for inclusion in the propensity matching. The average age of the population was 59% and 59% male. Overall readmission rate was 8.0%. Median time to readmission was 14 days. In the propensity score matched sample, readmitted patients had higher rates of organ space infection (28% vs 2% and p < 0.0001), bile leak (26% vs 1% and p < 0.0001), and liver failure (9% vs 2% and p = 0.042). There was no difference in LOS (7 days versus six days and p = 0.40), overall survival (median 39.7 vs 41.0 months and p = 0.79), or rate of adjuvant therapy (68% for both and p > 0.99). Conclusion: Patients readmitted for intermediate and late complications after surgery for CLM can recover and receive adjuvant therapy with no adverse effect on overall survival. Organ space infection, bile leak, and liver failure are highly associated with readmission.
- 12 June 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (7) , 1974-1981
Open AccessReadmissions After Surgery for Colorectal Liver Metastases: A Propensity Score Analysis From the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC)
Background: Readmission is considered as a surgical quality indicator. More data regarding predictors of readmission and outcomes after surgery for colorectal liver metastasis are needed. Using a propensity score match to create a 1:2 match of cases:controls for 90‐day. Readmission, the matching variables used for balance included age, tumor size, estimated blood loss, and type of resection (minor or major). T‐tests were used for continuous measures, Fisher's exact test was used for categorical data, and the Kaplan–Meier method was used to estimate survival. p < 0.05 was considered significant. Methods: Retrospectively examined 935 patients with CLM from 2000 to 2018. Using a propensity score match to create a 1:2 match of cases:controls for 90‐day. Readmission, the matching variables used for balance included age, tumor size, estimated blood loss, and type of resection (minor or major). T‐tests were used for continuous measures, Fisher's exact test was used for categorical data, and the Kaplan–Meier method was used to estimate survival. p < 0.05 was considered significant. Results: 935 patients were included in the initial sample with 896 eligible for inclusion in the propensity matching. The average age of the population was 59% and 59% male. Overall readmission rate was 8.0%. Median time to readmission was 14 days. In the propensity score matched sample, readmitted patients had higher rates of organ space infection (28% vs 2% and p < 0.0001), bile leak (26% vs 1% and p < 0.0001), and liver failure (9% vs 2% and p = 0.042). There was no difference in LOS (7 days versus six days and p = 0.40), overall survival (median 39.7 vs 41.0 months and p = 0.79), or rate of adjuvant therapy (68% for both and p > 0.99). Conclusion: Patients readmitted for intermediate and late complications after surgery for CLM can recover and receive adjuvant therapy with no adverse effect on overall survival. Organ space infection, bile leak, and liver failure are highly associated with readmission.
- 7 May 2025
- Published by Springer Nature
- p. 199-209
Hepatic Arterial Infusion Therapy: Strategies for Safe Long-term Arterial Infusions
- 7 May 2025
- Published by Springer Nature
- p. 199-209
Hepatic Arterial Infusion Therapy: Strategies for Safe Long-term Arterial Infusions
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 240 (4) , 463-471
Outcomes for Gastrectomy During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongastric Primaries: 30-Year Experience
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival for patients with peritoneal surface malignancy. Completeness of cytoreduction correlates with prognosis. The role of gastrectomy in these patients is not well described. STUDY DESIGN: A total of 1868 patients who underwent CRS+HIPEC for nongastric primary between 1991 and 2024 were analyzed from a prospective database. Patients were stratified by gastrectomy extent and their outcomes compared with no-gastrectomy patients. Continuous variables are presented as mean (SD), categorical variables as N (%), and values considered statistically significant at <0.05. RESULTS: No differences were observed in baseline demographics between the gastrectomy and no-gastrectomy groups. There were 23 major, 45 distal, and 77 wedge gastrectomies (n = 145, 7.76%). Appendiceal was the most common neoplasm in the gastrectomy groups (major: 96%, distal: 91%, wedge: 68%, no gastrectomy: 53%). Gastrectomy patients had higher median peritoneal carcinomatosis index (PCI) (major: 27 [7.0], distal: 24 [7.0], wedge: 19 [10.3], no-gastrectomy: 14 [9.5]; p < 0.001), R2 resection (major: 96%, distal: 89%, wedge: 60%, no-gastrectomy: 45%; p < 0.001), severe complications (major: 30%, distal: 27%, wedge: 19%, no-gastrectomy: 12%; p < 0.001), length of stay (major: 24 [15.2], distal: 23 [25.7], wedge: 18 [22.2], no-gastrectomy: 12 [12.5] days; p < 0.001), and 30-day mortality (major: 17%, distal: 11%, wedge: 10%, no-gastrectomy: 5%; p < 0.001). There was no difference in 30-day readmission or recurrence. On multivariate analysis, gastrectomy was not independently associated with overall survival (p = 0.18). CONCLUSIONS: Approximately 8% of patients who underwent CRS+HIPEC for nongastric primaries underwent gastrectomy. Gastrectomy patients were more likely to have higher PCI and incomplete resections with increased complications and mortality. PCI, resection status, lymph nodes, tumor grade, and primary site, but not gastrectomy type, are significantly associated with overall survival.
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 240 (4) , 463-471
Outcomes for Gastrectomy During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongastric Primaries: 30-Year Experience
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival for patients with peritoneal surface malignancy. Completeness of cytoreduction correlates with prognosis. The role of gastrectomy in these patients is not well described. STUDY DESIGN: A total of 1868 patients who underwent CRS+HIPEC for nongastric primary between 1991 and 2024 were analyzed from a prospective database. Patients were stratified by gastrectomy extent and their outcomes compared with no-gastrectomy patients. Continuous variables are presented as mean (SD), categorical variables as N (%), and values considered statistically significant at <0.05. RESULTS: No differences were observed in baseline demographics between the gastrectomy and no-gastrectomy groups. There were 23 major, 45 distal, and 77 wedge gastrectomies (n = 145, 7.76%). Appendiceal was the most common neoplasm in the gastrectomy groups (major: 96%, distal: 91%, wedge: 68%, no gastrectomy: 53%). Gastrectomy patients had higher median peritoneal carcinomatosis index (PCI) (major: 27 [7.0], distal: 24 [7.0], wedge: 19 [10.3], no-gastrectomy: 14 [9.5]; p < 0.001), R2 resection (major: 96%, distal: 89%, wedge: 60%, no-gastrectomy: 45%; p < 0.001), severe complications (major: 30%, distal: 27%, wedge: 19%, no-gastrectomy: 12%; p < 0.001), length of stay (major: 24 [15.2], distal: 23 [25.7], wedge: 18 [22.2], no-gastrectomy: 12 [12.5] days; p < 0.001), and 30-day mortality (major: 17%, distal: 11%, wedge: 10%, no-gastrectomy: 5%; p < 0.001). There was no difference in 30-day readmission or recurrence. On multivariate analysis, gastrectomy was not independently associated with overall survival (p = 0.18). CONCLUSIONS: Approximately 8% of patients who underwent CRS+HIPEC for nongastric primaries underwent gastrectomy. Gastrectomy patients were more likely to have higher PCI and incomplete resections with increased complications and mortality. PCI, resection status, lymph nodes, tumor grade, and primary site, but not gastrectomy type, are significantly associated with overall survival.
- 10 October 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (8) , 1611-1616
Surgical Approach and Length of Stay in Octogenarians Undergoing Pancreatic Resection for Malignancy
Introduction: Pancreatic surgery often has a lengthy recovery in the elderly. Minimally invasive surgery (MIS) can decrease length of stay (LOS), but it is unknown if this benefit applies to octogenarians (Age > 79).Methods: The NSQIP database was used to determine if MIS approaches were associated with reduced LOS among octogenarians undergoing pancreaticoduodenectomy (Whipple) or distal pancreatectomy (Distal). Operative approaches were classified as “Open” or “MIS” and propensity score (PS) matching was performed.Results: For the Whipple, 1665 Open and 101 MIS procedures occurred (median LOS 9, 8 days, p = 0.584). For Distal, 472 Open and 223 MIS procedures occurred (median LOS 6, 5 days, p < 0.01). After PS matching, there were 202 Whipple (101 per group) and 446 Distal (223 per group) patients. There was no difference in LOS by approach in the Whipple group (p = 0.546). The median LOS was 9 (IQR 7–15), Open and 8 (IQR 6–13), MIS. For Distal, there was a difference in LOS in the Open versus MIS approach (p < 0.01) and the median LOS was 6 (IQR 5–8) and 5 (IQR 4–6).Conclusions: Among octogenarians the MIS approach was associated with decreased LOS in distal pancreatectomies, but not in pancreaticoduodenectomies.
- 10 October 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (8) , 1611-1616
Surgical Approach and Length of Stay in Octogenarians Undergoing Pancreatic Resection for Malignancy
Introduction: Pancreatic surgery often has a lengthy recovery in the elderly. Minimally invasive surgery (MIS) can decrease length of stay (LOS), but it is unknown if this benefit applies to octogenarians (Age > 79).Methods: The NSQIP database was used to determine if MIS approaches were associated with reduced LOS among octogenarians undergoing pancreaticoduodenectomy (Whipple) or distal pancreatectomy (Distal). Operative approaches were classified as “Open” or “MIS” and propensity score (PS) matching was performed.Results: For the Whipple, 1665 Open and 101 MIS procedures occurred (median LOS 9, 8 days, p = 0.584). For Distal, 472 Open and 223 MIS procedures occurred (median LOS 6, 5 days, p < 0.01). After PS matching, there were 202 Whipple (101 per group) and 446 Distal (223 per group) patients. There was no difference in LOS by approach in the Whipple group (p = 0.546). The median LOS was 9 (IQR 7–15), Open and 8 (IQR 6–13), MIS. For Distal, there was a difference in LOS in the Open versus MIS approach (p < 0.01) and the median LOS was 6 (IQR 5–8) and 5 (IQR 4–6).Conclusions: Among octogenarians the MIS approach was associated with decreased LOS in distal pancreatectomies, but not in pancreaticoduodenectomies.
- 25 August 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (8) , 1654-1661
Prognostic implications of margin status in association with systemic treatment in a cohort study of patients with resection of colorectal liver metastases
Background: This study investigates the impact of margin status after colorectal liver metastasis (CLM) resection on outcomes of patients after neoadjuvant treatment versus those who underwent upfront resection.Methods: An international collaborative database of CLM patients who underwent surgical resection was used. Proportional hazard regression models were created for single and multivariable models to assess the relationship between independent measures and median overall survival (mOS).Results: R1 was associated with worse OS in the neoadjuvant group (mOS: 51.8 m for R0 vs. 26.0 m for R1; HR: 2.18). In the patients who underwent upfront surgery, R1 was not associated with OS. (mOS: 46.7 m for R0 vs. 42.6 m for R1). When patients with R1 in each group were stratified by adjuvant treatment, there was no significant difference in the neoadjuvant group, while in the upfront surgery group with R1, adjuvant treatment was associated with significant improvement in OS (mOS: 42.6 m for adjuvant vs. 25.0 m for no adjuvant treatment; HR: 0.21).Conclusion: R1 is associated with worse outcomes in the patients who receive neoadjuvant treatment with no significant improvement with the addition of adjuvant therapy, likely representing an aggressive tumor biology. R1 did not impact OS in patients with upfront surgery who received postoperative chemotherapy.
- 25 August 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (8) , 1654-1661
Prognostic implications of margin status in association with systemic treatment in a cohort study of patients with resection of colorectal liver metastases
Background: This study investigates the impact of margin status after colorectal liver metastasis (CLM) resection on outcomes of patients after neoadjuvant treatment versus those who underwent upfront resection.Methods: An international collaborative database of CLM patients who underwent surgical resection was used. Proportional hazard regression models were created for single and multivariable models to assess the relationship between independent measures and median overall survival (mOS).Results: R1 was associated with worse OS in the neoadjuvant group (mOS: 51.8 m for R0 vs. 26.0 m for R1; HR: 2.18). In the patients who underwent upfront surgery, R1 was not associated with OS. (mOS: 46.7 m for R0 vs. 42.6 m for R1). When patients with R1 in each group were stratified by adjuvant treatment, there was no significant difference in the neoadjuvant group, while in the upfront surgery group with R1, adjuvant treatment was associated with significant improvement in OS (mOS: 42.6 m for adjuvant vs. 25.0 m for no adjuvant treatment; HR: 0.21).Conclusion: R1 is associated with worse outcomes in the patients who receive neoadjuvant treatment with no significant improvement with the addition of adjuvant therapy, likely representing an aggressive tumor biology. R1 did not impact OS in patients with upfront surgery who received postoperative chemotherapy.
- 4 August 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (3) , 516-522
Resection versus resection with ablation: Analysis from the colorectal liver operative metastasis international collaborative
Background: Thermal ablation has recently become a key therapy for the treatment of colorectal liver metastasis (CLM). However, the role of ablation in combination with resection has not yet been firmly established. We hypothesize that in patients with CLM, those who undergo liver resection with ablation (RA) have similar outcomes compared with those who undergo liver resection only.Methods: We reviewed a multicenter international database of 906 surgical procedures for CLM from 5 high volume hepatobiliary surgical units. Patients undergoing RA (n = 63) were matched based on the number of lesions and tumor size using a 1:1 balanced propensity score analysis with those having resection only (n = 63). Our primary outcomes were overall survival (OS) and disease‐free survival (DFS).Results: The mean age of our cohort was 58 ± 11 years, with 43% females. With a median follow‐up of 70.8 months, patients in the resection and RA group had a median OS of 45.1 and 54.8 months (p = 0.71), respectively. The median DFS was 22.7 and 14.2 months (p = 0.045), respectively. Using a multivariate Cox proportional hazards regression model, the treatment approach was not associated with OS (p = 0.94) or DFS (p = 0.059). A higher number of lesions is independently associated with worse DFS (hazard ratio: 1.12, p < 0.01). When there was disease recurrence, the region of recurrence was similar between the RA versus resection only groups (p = 0.27), but there was a shorter time to recurrence in the RA group (p = 0.002).Conclusion: For CLM, the treatment approach was not significantly associated with OS or DFS, while tumor biology likely played an important role. Prospective research on the quality and effectiveness of thermal ablation combined with hepatic resection is warranted.
- 4 August 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (3) , 516-522
Resection versus resection with ablation: Analysis from the colorectal liver operative metastasis international collaborative
Background: Thermal ablation has recently become a key therapy for the treatment of colorectal liver metastasis (CLM). However, the role of ablation in combination with resection has not yet been firmly established. We hypothesize that in patients with CLM, those who undergo liver resection with ablation (RA) have similar outcomes compared with those who undergo liver resection only.Methods: We reviewed a multicenter international database of 906 surgical procedures for CLM from 5 high volume hepatobiliary surgical units. Patients undergoing RA (n = 63) were matched based on the number of lesions and tumor size using a 1:1 balanced propensity score analysis with those having resection only (n = 63). Our primary outcomes were overall survival (OS) and disease‐free survival (DFS).Results: The mean age of our cohort was 58 ± 11 years, with 43% females. With a median follow‐up of 70.8 months, patients in the resection and RA group had a median OS of 45.1 and 54.8 months (p = 0.71), respectively. The median DFS was 22.7 and 14.2 months (p = 0.045), respectively. Using a multivariate Cox proportional hazards regression model, the treatment approach was not associated with OS (p = 0.94) or DFS (p = 0.059). A higher number of lesions is independently associated with worse DFS (hazard ratio: 1.12, p < 0.01). When there was disease recurrence, the region of recurrence was similar between the RA versus resection only groups (p = 0.27), but there was a shorter time to recurrence in the RA group (p = 0.002).Conclusion: For CLM, the treatment approach was not significantly associated with OS or DFS, while tumor biology likely played an important role. Prospective research on the quality and effectiveness of thermal ablation combined with hepatic resection is warranted.
- 23 November 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (2) , 1071-1072
ASO Visual Abstract: Distance Traveled and Disparities in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 23 November 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (2) , 1071-1072
ASO Visual Abstract: Distance Traveled and Disparities in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Open Access
- 22 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 85-90
Comparison of outcomes between surgical treatment of colorectal cancer metastatic to the liver and the peritoneum: Review of the literature
Background: Liver and peritoneum are two of the most common sites of colorectal metastases.Methods: We searched for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum.Conclusion: Cytoreductive surgery/heated intraperitoneal chemotherapy has a similar safety profile and survival outcomes as hepatectomy for colorectal metastases after stratifying by resection status and should be incorporated earlier in the management algorithm for colorectal cancer patients with peritoneal metastasesMethods: We performed a wide search on PubMed, EMBASE, and Google Scholar for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum. We focused on studies comparing their perioperative clinical outcomes as well as their oncological outcomes. The following words were included in the search: comparison, outcomes, metastasectomy, colorectal cancer, liver, peritoneal surface disease, hepatectomy, and cytoreduction.Results: One hundred and twenty studies were evaluated. Six of these studies met the criteria for this review.
- 22 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 85-90
Open AccessComparison of outcomes between surgical treatment of colorectal cancer metastatic to the liver and the peritoneum: Review of the literature
Background: Liver and peritoneum are two of the most common sites of colorectal metastases.Methods: We searched for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum.Conclusion: Cytoreductive surgery/heated intraperitoneal chemotherapy has a similar safety profile and survival outcomes as hepatectomy for colorectal metastases after stratifying by resection status and should be incorporated earlier in the management algorithm for colorectal cancer patients with peritoneal metastasesMethods: We performed a wide search on PubMed, EMBASE, and Google Scholar for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum. We focused on studies comparing their perioperative clinical outcomes as well as their oncological outcomes. The following words were included in the search: comparison, outcomes, metastasectomy, colorectal cancer, liver, peritoneal surface disease, hepatectomy, and cytoreduction.Results: One hundred and twenty studies were evaluated. Six of these studies met the criteria for this review.